Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06040372 · ClinicalTrials.gov registry record · Phase 1
A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects
A Phase 1 study, sponsored by LG Chem.
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT06040372 is a Phase 1 study that has completed, run by LG Chem. The registered enrollment target is 112 participants.
The verdict
NCT06040372, a Phase 1 study, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
The aim of this 4-weeks randomized double-blind placebo-controlled single and multiple ascending dose study is to assess the Safety and Tolerability of LB54640 in Healthy overweight and obese subjects
Interventions
- DRUG Placebo
- DRUG LB64640
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2020-03-16 |
| Est. Completion | 2022-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06040372
The ClinicalTrials.gov registry entry for NCT06040372 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LG Chem, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06040372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06040372 about?
NCT06040372 is a clinical study titled "A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects". The aim of this 4-weeks randomized double-blind placebo-controlled single and multiple ascending dose study is to assess the Safety and Tolerability of LB54640 in Healthy overweight and obese subjects
What is the current status of trial NCT06040372?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2020-03-16. Estimated completion is 2022-07-30.
What interventions are being tested in trial NCT06040372?
The interventions under investigation include: Placebo (DRUG), LB64640 (DRUG).
Who is sponsoring clinical trial NCT06040372?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.